Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma. - Yu K; Tidwell RS; Bathala TK; Sheth RA; Karki M; Chen J; Qian J; Duan F; Perelli L; Soeung M; Rao P; Siefker-Radtke AO; et al. (Clinical cancer research : an official journal of the American Association for Cancer Research, 2026)